MDT

87.67

-1.52%↓

VEEV

234.11

-1.12%↓

A

116.65

-1.95%↓

HQY

86.99

-1.99%↓

PDCO

31.23

-0.03%↓

MDT

87.67

-1.52%↓

VEEV

234.11

-1.12%↓

A

116.65

-1.95%↓

HQY

86.99

-1.99%↓

PDCO

31.23

-0.03%↓

MDT

87.67

-1.52%↓

VEEV

234.11

-1.12%↓

A

116.65

-1.95%↓

HQY

86.99

-1.99%↓

PDCO

31.23

-0.03%↓

MDT

87.67

-1.52%↓

VEEV

234.11

-1.12%↓

A

116.65

-1.95%↓

HQY

86.99

-1.99%↓

PDCO

31.23

-0.03%↓

MDT

87.67

-1.52%↓

VEEV

234.11

-1.12%↓

A

116.65

-1.95%↓

HQY

86.99

-1.99%↓

PDCO

31.23

-0.03%↓

Search

Allogene Therapeutics Inc

Closed

SectorHealthcare

1.56 0.65

Overview

Share price change

24h

Current

Min

1.52

Max

1.56

Key metrics

By Trading Economics

Income

6.4M

-60M

EPS

-0.28

Profit margin

-295,454.545

Employees

226

EBITDA

6.8M

-56M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+448.39% upside

Dividends

By Dow Jones

Next Earnings

12 May 2025

Market Stats

By TradingEconomics

Market Cap

-92M

365M

Previous open

0.91

Previous close

1.56

News Sentiment

By Acuity

62%

38%

326 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Allogene Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

30 Mar 2025, 23:43 UTC

Market Talk

Gold Edges Higher, Supported by Looming U.S. Tariffs -- Market Talk

30 Mar 2025, 23:41 UTC

Market Talk

Global Equities Roundup: Market Talk

30 Mar 2025, 23:41 UTC

Market Talk

Nikkei May Fall Amid Concerns About U.S. Tariffs, Borrowing Costs -- Market Talk

30 Mar 2025, 23:12 UTC

Earnings

Tsingtao Brewery 2024 Net CNY4.34B Vs. Net CNY4.27B >0168.HK

30 Mar 2025, 23:12 UTC

Earnings

Tsingtao Brewery Board Proposes Final Dividend of CNY2.20/Share >0168.HK

30 Mar 2025, 23:12 UTC

Earnings

Tsingtao Brewery 2024 Rev CNY32.14B Vs. CNY33.94B >0168.HK

30 Mar 2025, 22:30 UTC

Earnings

Great Wall Motor 2024 Net CNY12.69 Vs. Net CNY7.02B >2333.HK

30 Mar 2025, 22:30 UTC

Earnings

Great Wall Motor: Higher Overseas Vehicle Sales Among Factors Supporting Results >2333.HK

30 Mar 2025, 22:30 UTC

Earnings

Great Wall Motor 2024 Rev CNY202.20B Vs. CNY173.21B >2333.HK

30 Mar 2025, 21:44 UTC

Market Talk

Barclays Favors Core Bonds Over Equities as Tariffs Loom -- Market Talk

30 Mar 2025, 21:24 UTC

Market Talk

Early Polling Shows Labor's Support Firms Before Australia Vote -- Market Talk

30 Mar 2025, 21:23 UTC

Top News

Trump Team Weighs Broader, Higher Tariffs -- WSJ

30 Mar 2025, 16:23 UTC

Top News

Tesla's EV Credit Income Is Still Rolling In -- for Now -- Barrons.com

30 Mar 2025, 09:30 UTC

Top News

The AI Data-Center Boom Is Coming to America's Heartland -- WSJ

30 Mar 2025, 09:30 UTC

Top News

Tariffs on Screws Are Already Hitting Manufacturers -- WSJ

29 Mar 2025, 13:00 UTC

Top News

Trump's Trade War Arrives in America's Heartland -- WSJ

29 Mar 2025, 11:00 UTC

Top News

Selling Your House This Spring? You Might Need to Cut the Price -- Heard on the Street -- WSJ

29 Mar 2025, 09:30 UTC

Top News

The Auto Union Boss Who Went From Trump Foe to Tariff Cheerleader -- WSJ

29 Mar 2025, 08:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

29 Mar 2025, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

29 Mar 2025, 00:00 UTC

Top News

The Drone-Delivery Service Beating Amazon to Your Front Door -- WSJ

28 Mar 2025, 23:16 UTC

Acquisitions, Mergers, Takeovers

CoreWeave Debuts: A Big IPO in a Slow Year -- Barrons.com

28 Mar 2025, 22:21 UTC

Top News

Inflation, Consumer Fears Fuel Stock Selloff -- WSJ

28 Mar 2025, 21:49 UTC

Top News

FCC Investigates Disney for DEI Practices, Chair Says -- 2nd Update

28 Mar 2025, 21:28 UTC

Top News

Stocks Fall on Tariff, Consumer Sentiment Fears -- WSJ

28 Mar 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

28 Mar 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28 Mar 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28 Mar 2025, 20:40 UTC

Top News

OpenAI's Latest Funding Round Comes With a $20 Billion Catch -- WSJ

28 Mar 2025, 20:36 UTC

Top News

Consumers' Mood Sours in March With Gloomier Economic Outlook -- 4th Update

Peer Comparison

Price change

Allogene Therapeutics Inc Forecast

Price Target

By TipRanks

448.39% upside

12 Months Forecast

Average 8.5 USD  448.39%

High 14 USD

Low 4 USD

Based on 12 Wall Street analysts offering 12 month price targets forAllogene Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

11

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

1.53 / 1.69Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

326 / 386 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.